EGFR and colorectal cancer: BRAF p.V600E missense mutation is associated with poor prognosis in colorectal cancer and according to some recent reports, it has negative predictive value in anti-EGFR antibody therapy [18], though this has yet to reach sufficient levels of evidence to update clinical guidance [9–11, 37].